{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T07:33:25Z","timestamp":1771054405347,"version":"3.50.1"},"update-to":[{"DOI":"10.1002\/14651858.cd000208","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2018,3,19]],"date-time":"2018-03-19T00:00:00Z","timestamp":1521417600000}}],"reference-count":206,"publisher":"Wiley","issue":"3","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd000208.pub2","type":"journal-article","created":{"date-parts":[[2018,3,19]],"date-time":"2018-03-19T01:16:25Z","timestamp":1521422185000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Miscellaneous treatments for antipsychotic-induced tardive dyskinesia"],"prefix":"10.1002","volume":"2018","author":[{"given":"Karla","family":"Soares-Weiser","sequence":"first","affiliation":[{"name":"Cochrane; Editorial & Methods Department; St Albans House, 57 - 59 Haymarket London UK SW1Y 4QX"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Rathbone","sequence":"additional","affiliation":[{"name":"Bond University; Faculty of Health Sciences and Medicine; Robina Gold Coast Queensland Australia 4229"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuke","family":"Ogawa","sequence":"additional","affiliation":[{"name":"Kyoto University Graduate School of Medicine\/School of Public Health; Department of Health Promotion and Human Behavior; Yoshida Konoe-cho, Sakyo-ku Kyoto Japan 606-8501"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiyomi","family":"Shinohara","sequence":"additional","affiliation":[{"name":"Kyoto University Graduate School of Medicine \/ School of Public Health; Department of Health Promotion and Human Behavior; Yoshida Konoe-cho, Sakyo-ku Kyoto Japan 601-8501"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanna","family":"Bergman","sequence":"additional","affiliation":[{"name":"Cochrane; Cochrane Response; St Albans House 57-59 Haymarket London UK SW1Y 4QX"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2018,3,19]]},"reference":[{"issue":"5","key":"10.1002\/14651858.CD000208.pub2-BIB0001|cit1","first-page":"324","article-title":"The dyskinesias: a new approach","volume":"32","author":"Bucci","year":"1971","journal-title":"Diseases of the Nervous System"},{"issue":"5","key":"10.1002\/14651858.CD000208.pub2-BIB0002|cit2","first-page":"281","article-title":"A controlled study on the treatment of tardive dyskinesia using 1-stepholidine","volume":"21","author":"Cai","year":"1988","journal-title":"Chinese Journal of Neurology and Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD000208.pub2-BIB0003|cit3","first-page":"252","article-title":"Effectiveness of melatonin in tardive dyskinesia","volume":"52","author":"Castro","year":"2011","journal-title":"Investigacio\u0301n Cli\u0301nica"},{"key":"10.1002\/14651858.CD000208.pub2-BIB0004|cit4","unstructured":"Elmsley R Oosthuizen PP Double-blind, randomized, parallel-group comparison of ethyl-eicosapentaenoic acid (ethyl-EP A) versus placebo as add-on medication in 84 patients with established tardive dyskinesia Stanley Foundation Research Programs 2002"},{"key":"10.1002\/14651858.CD000208.pub2-BIB0007|cit5","unstructured":"Emsley R A double-blind, randomised, parallel-group comparison of ethyl-eicosapentaenoic acid (ethyl-epa) versus placebo as add-on medication in patients with established tardive dyskinesia https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00114595 2005"},{"key":"10.1002\/14651858.CD000208.pub2-BIB0008|cit6","unstructured":"Emsley R Ethyl eicosapentanoic acid for tardive dyskinesia Stanley Foundation Research Programs 2009"},{"issue":"1","key":"10.1002\/14651858.CD000208.pub2-BIB0005|cit7","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.schres.2006.03.023","article-title":"The effects of eicosapentaenoic acid in tardive dyskinesia: a randomized, placebo-controlled trial","volume":"84","author":"Emsley","year":"2006","journal-title":"Schizophrenia Research"},{"issue":"3","key":"10.1002\/14651858.CD000208.pub2-BIB0006|cit8","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.psychres.2007.06.029","article-title":"Safety of the omega-3 fatty acid, eicosapentaenoic acid (EPA) in psychiatric patients: results from a randomized, placebo-controlled trial","volume":"161","author":"Emsley","year":"2008","journal-title":"Psychiatry Research"},{"issue":"5-6","key":"10.1002\/14651858.CD000208.pub2-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/0364-7722(79)90008-0","article-title":"The effects of papaverine in tardive dyskinesia","volume":"3","author":"Gardos","year":"1979","journal-title":"Progress in Neuro-Psychopharmacology & Biological Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD000208.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/0306-4530(85)90011-3","article-title":"Estrogen replacement and tardive dyskinesia","volume":"10","author":"Glazer","year":"1985","journal-title":"Psychoneuroendocrinology"},{"key":"10.1002\/14651858.CD000208.pub2-BIB0011|cit11","unstructured":"Glover O Alternative treatment modalities for drug induced psychomotor dysfunctions PhD dissertation submitted to the Wright Institute 1980 150"},{"issue":"10","key":"10.1002\/14651858.CD000208.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/0006-3223(93)90119-X","article-title":"A placebo-controlled trial of selegiline (L-deprenyl) in the treatment of tardive dyskinesia","volume":"33","author":"Goff","year":"1993","journal-title":"Biological Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD000208.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF00433006","article-title":"Effect of Co-dergocrine mesylate on tardive dyskinesia. A preliminary report","volume":"79","author":"Hajioff","year":"1983","journal-title":"Psychopharmacology"},{"issue":"10","key":"10.1002\/14651858.CD000208.pub2-BIB0014|cit14","first-page":"2177","article-title":"Treatment of tardive dyskinesia with ceruletide: a double-blind placebo-controlled study","volume":"44","author":"Kojima","year":"1989","journal-title":"Saishin-Igaku"},{"issue":"2","key":"10.1002\/14651858.CD000208.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/0165-1781(92)90127-O","article-title":"Treatment of tardive dyskinesia with ceruletide: a double-blind, placebo-controlled study","volume":"43","author":"Kojima","year":"1992","journal-title":"Psychiatry Research"},{"issue":"4","key":"10.1002\/14651858.CD000208.pub2-BIB0016|cit16","first-page":"421","article-title":"Double-blind trial of cyproheptadine on neuroleptic induced tardive dyskinesia","volume":"21","author":"Koshino","year":"1979","journal-title":"Clinical Psychiatry [Seishin Igaku]"},{"issue":"6","key":"10.1002\/14651858.CD000208.pub2-BIB0017|cit17","first-page":"627","article-title":"A double-blind clinical trial of dihydrogenated ergot alkaloids in antipsychotic-induced tardive dyskinesia","volume":"25","author":"Koshino","year":"1983","journal-title":"Clinical Psychiatry [Seishin Igaku]"},{"issue":"11","key":"10.1002\/14651858.CD000208.pub2-BIB0018|cit18","first-page":"3","article-title":"Piracetam reduces TD symptomstardive dyskinesia","volume":"18","author":"Anon","year":"2007","journal-title":"Brown University Psychopharmacology Update"},{"key":"10.1002\/14651858.CD000208.pub2-BIB0019|cit19","unstructured":"Lerner V Piracetam for tardive dyskinesia Stanley Foundation Research Programs 2009"},{"issue":"7","key":"10.1002\/14651858.CD000208.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.4088\/JCP.v68n0709","article-title":"Efficacy of piracetam in the treatment of tardive dyskinesia in schizophrenic patients: a randomized, double-blind, placebo-controlled crossover study","volume":"68","author":"Libov","year":"2007","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD000208.pub2-BIB0021|cit21","unstructured":"NCT00190008 Therapeutic use of piracetam for treatment of patients suffering from tardive dyskinesia - a double blind, placebo-controlled crossover study http:\/\/www.clinicaltrials.gov. 2005"},{"issue":"3","key":"10.1002\/14651858.CD000208.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1017\/S0033291700047498","article-title":"Failure of lithium treatment in established tardive dyskinesia","volume":"10","author":"Mackay","year":"1980","journal-title":"Psychological Medicine"},{"issue":"4","key":"10.1002\/14651858.CD000208.pub2-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/0278-5846(88)90112-1","article-title":"The effect of ceruletide on tardive dyskinesia: a double-blind placebo-controlled study","volume":"12","author":"Matsunaga","year":"1988","journal-title":"Progress in Neuro-Psychopharmacology and Biological Psychiatry"},{"issue":"5","key":"10.1002\/14651858.CD000208.pub2-BIB0024|cit24","first-page":"884","article-title":"Ritanserin in tardive dyskinesia: A double-blind crossover study versus placebo","volume":"46","author":"Meco","year":"1989","journal-title":"Current Therapeutics Research"},{"key":"10.1002\/14651858.CD000208.pub2-BIB0027|cit25","unstructured":"Mosnik DM Phenylalanine loading effects on tardive dyskinesia severity in schizophrenics Master of Science dissertation submitted to the Finch University of Health Sciences, USA. 1994"},{"issue":"2","key":"10.1002\/14651858.CD000208.pub2-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/S0893-133X(96)00054-1","article-title":"Tardive dyskinesia exacerbated after ingestion of phenylalanine by schizophrenic patients","volume":"16","author":"Mosnik","year":"1997","journal-title":"Neuropsychopharmacology"},{"issue":"1, 2","key":"10.1002\/14651858.CD000208.pub2-BIB0025|cit27","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/0920-9964(95)95640-U","article-title":"Phenylalanine loading effects on tardive dyskinesia severity in schizophrenics","volume":"15","author":"Mosnik","year":"1995","journal-title":"Schizophrenia Research"},{"issue":"4","key":"10.1002\/14651858.CD000208.pub2-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1159\/000116678","article-title":"Low doses of insulin as a treatment of tardive dyskinesia: conjuncture or conjecture?","volume":"31","author":"Mouret","year":"1991","journal-title":"European Neurology"},{"issue":"16 SUPPL. 1","key":"10.1002\/14651858.CD000208.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"S27.007","DOI":"10.1212\/WNL.86.16_supplement.S27.007","article-title":"A Phase 2 Study of valbenazine (NBI-98854) for treatment of tardive dyskinesia: KINECT 2","volume":"86","author":"Factor","year":"2016","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD000208.pub2-BIB0030|cit30","unstructured":"NCT01733121 Nbi-98854 dose titration study for the treatment of tardive dyskinesia http:\/\/ClinicalTrials.gov\/show\/NCT01733121 (accessed on 6 October 2017) 2012"},{"issue":"12","key":"10.1002\/14651858.CD000208.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1002\/mds.26330","article-title":"NBI-98854, A selective monoamine transport inhibitor for the treatment of tardive dyskinesia: A randomized, double-blind, placebo-controlled study","volume":"30","author":"O'Brien","year":"2015","journal-title":"Movement Disorders"},{"key":"10.1002\/14651858.CD000208.pub2-BIB0032|cit32","first-page":"S305","article-title":"Kinect 2: NBI-98854 treatment of moderate to severe tardive dyskinesia","volume":"29","author":"O'Brien","journal-title":"18th International Congress of Parkinson's Disease and Movement Disorders, Stockholm, Sweden"},{"issue":"2","key":"10.1002\/14651858.CD000208.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1017\/S0033291700046778","article-title":"Co-dergocrine (hydergine) in the treatment of tardive dyskinesia","volume":"12","author":"Rastogi","year":"1982","journal-title":"Psychological Medicine"},{"issue":"6","key":"10.1002\/14651858.CD000208.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1176\/appi.ajp.160.6.1117","article-title":"Efficacy of the branched-chain amino acids in the treatment of tardive dyskinesia in men","volume":"160","author":"Richardson","year":"2003","journal-title":"American Journal of Psychiatry"},{"issue":"8","key":"10.1002\/14651858.CD000208.pub2-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"556","DOI":"10.4088\/JCP.v61n0803","article-title":"Is melatonin treatment effective for tardive dyskinesia?","volume":"61","author":"Shamir","year":"2000","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD000208.pub2-BIB0037|cit36","unstructured":"Shamir EZ Barak F Shalman I Landon N Zisapel N Elizur A Melatonin treatment for tardive dyskinesia: a double-blind, placebo-controlled, cross-over study Annual Meeting of the American Psychiatric Association; 2001 May 5-10; LA, USA 2001"},{"key":"10.1002\/14651858.CD000208.pub2-BIB0036|cit37","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1001\/archpsyc.58.11.1049","article-title":"Melatonin treatment for tardive dyskinesia: a double-blind, placebo-controlled, cross-over study","volume":"58","author":"Shamir","year":"2001","journal-title":"Archives of General Psychiatry"},{"issue":"6","key":"10.1002\/14651858.CD000208.pub2-BIB0038|cit38","first-page":"391","article-title":"Melatonin in treatment of schizophrenia with tardive dyskinesia: A comparison study of cognitive function","volume":"19","author":"Shi","year":"2009","journal-title":"Linchuang Jingshen Yixue Zazhi"},{"key":"10.1002\/14651858.CD000208.pub2-BIB0039|cit39","unstructured":"NCT00175955 An 8-week exploratory, double-blind, placebo controlled, randomized trial - evaluation of the efficacy and safety of levetiracetam up to 3000 mg\/day (250-500 mg oral tablets in bid administration) on neuroleptic-induced tardive dyskinesia in subjects with stable axis I psychiatric disorder, aged from at least 18 years to 80 years https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00175955 2005"},{"issue":"7","key":"10.1002\/14651858.CD000208.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1176\/ajp.143.7.912","article-title":"Essential fatty acid supplementation in tardive dyskinesia","volume":"143","author":"Wolkin","year":"1986","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD000208.pub2-BIB0041|cit41","unstructured":"NCT00291213 Levetiracetam treatment of tardive dyskinesia www.Clinical Trials.gov (https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00291213) 2006"},{"issue":"4","key":"10.1002\/14651858.CD000208.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"546","DOI":"10.4088\/JCP.v69n0405","article-title":"Effects of levetiracetam on tardive dyskinesia: A randomized, double-blind, placebo-controlled study","volume":"69","author":"Woods","year":"2008","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD000208.pub2-BIB0043|cit43","first-page":"365","article-title":"Promethazine treatment of tardive dyskinesia: a double blind placebo controlled study","volume":"13","author":"Yang","year":"1999","journal-title":"Chinese Mental Health Journal"},{"key":"10.1002\/14651858.CD000208.pub2-BIB0044|cit44","first-page":"202","article-title":"Treatment of tardive dyskinesia with buspirone","volume":"7","author":"Zeng","year":"1995","journal-title":"Medical Journal of Chinese Civil Administration"},{"key":"10.1002\/14651858.CD000208.pub2-BIB0045|cit45","first-page":"240","article-title":"Pemoline in the treatment of tardive dyskinesia","volume":"15","author":"Zeng","year":"1996","journal-title":"Chinese Journal of New Drugs and Clinical Remedies"},{"key":"10.1002\/14651858.CD000208.pub2-BIB0046|cit46","unstructured":"NCT00672373 Extract of ginkgo biloba and tardive dyskinesia www.ClinicalTrials.gov (https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00672373?term=NCT00672373&rank=1) 2008"},{"key":"10.1002\/14651858.CD000208.pub2-BIB0047|cit47","unstructured":"Zhang F Bigos K Weinberger D Genome-wide analysis of antipsychotic drug response in schizophrenia Proceedings of the 50th Annual Meeting of the American College of Neuropsychopharmacology; 2011 Dec 4-8; Waikoloa, Hawaii 2011 135"},{"issue":"5","key":"10.1002\/14651858.CD000208.pub2-BIB0048|cit48","doi-asserted-by":"publisher","first-page":"615","DOI":"10.4088\/JCP.09m05125yel","article-title":"Extract of Ginkgo biloba treatment for tardive dyskinesia in schizophrenia: a randomized, double-blind, placebo-controlled trial","volume":"72","author":"Zhang","year":"2011","journal-title":"Journal of Clinical Psychiatry"},{"issue":"S1","key":"10.1002\/14651858.CD000208.pub2-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1046\/j.1365-2125.2000.00155.x","article-title":"The effects of ziprasidone on steady-state lithium levels and renal clearance of lithium","volume":"49","author":"Apseloff","year":"2000","journal-title":"British Journal of Clinical Pharmacology"},{"key":"10.1002\/14651858.CD000208.pub2-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/BF00427638","article-title":"Enkephalin, morphine, and naxoxone in tardive dyskinesia","volume":"69","author":"Bjorndal","year":"1980","journal-title":"Psychopharmacology"},{"issue":"3","key":"10.1002\/14651858.CD000208.pub2-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1097\/00002826-198409000-00008","article-title":"Naloxone may be beneficial in the treatment of tardive dyskinesia","volume":"7","author":"Blum","year":"1984","journal-title":"Clinical Neuropharmacology"},{"issue":"4","key":"10.1002\/14651858.CD000208.pub2-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1007\/BF00207250","article-title":"Naloxone in tardive dyskinesia","volume":"93","author":"Blum","year":"1987","journal-title":"Psychopharmacology Berlin"},{"issue":"1","key":"10.1002\/14651858.CD000208.pub2-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/BF00369796","article-title":"Deanol in tardive dyskinesia: a double-blind study","volume":"222","author":"Bockenheimer","year":"1976","journal-title":"Archiv f\u00fcr Psychiatrie und Nervenkrankheiten"},{"issue":"2","key":"10.1002\/14651858.CD000208.pub2-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/BF00426727","article-title":"Tardive dyskinesia: a clinical test of the supersensitivity hypothesis","volume":"61","author":"Bowers","year":"1979","journal-title":"Psychopharmacology Berlin"},{"key":"10.1002\/14651858.CD000208.pub2-BIB0055|cit55","first-page":"538","article-title":"Des-tyr-gamma-endorphin in tardive dyskinesia","volume":"93","author":"Blum","journal-title":"Proceedings of the 3rd World Congress of Biological Psychiatry"},{"key":"10.1002\/14651858.CD000208.pub2-BIB0057|cit56","unstructured":"Casey DE Korsgaard S Gerlach J Des-tyr-gamma-endorphin in tardive dyskinesia Proceedings of the World Congress of Biological Psychiatry; 1981 June 28- July 3rd; Stockholm, Sweden 1981"},{"issue":"2","key":"10.1002\/14651858.CD000208.pub2-BIB0056|cit57","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1001\/archpsyc.1981.01780270044005","article-title":"Effect of des-tyrosine-gamma -endorphin in tardive dyskinesia","volume":"38","author":"Casey","year":"1981","journal-title":"Archives of General Psychiatry"},{"key":"10.1002\/14651858.CD000208.pub2-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1192\/bjp.172.1.78","article-title":"Informing patients about tardive dyskinesia: controlled trial of patient education","volume":"172","author":"Chaplin","year":"1998","journal-title":"British Journal of Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD000208.pub2-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1046\/j.1440-1614.2002.00979.x","article-title":"Informing patients about tardive dyskinesia: Four-year follow up of a trial of patient education","volume":"36","author":"Chaplin","year":"2002","journal-title":"Australian and New Zealand Journal of Psychiatry"},{"key":"10.1002\/14651858.CD000208.pub2-BIB0060|cit60","first-page":"153","article-title":"An educational session on tardive dyskinesia increased patients' knowledge at 6 months without affecting compliance or clinical stability","volume":"3","author":"Chaplin","year":"1998","journal-title":"Evidence-Based Medicine"},{"issue":"9","key":"10.1002\/14651858.CD000208.pub2-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1176\/appi.ajp.159.9.1596","article-title":"Randomized, placebo-controlled study of ethyl-eicosapentaenoic acid as supplemental treatment in schizophrenia","volume":"159","author":"Emsley","year":"2002","journal-title":"American Journal of Psychiatry"},{"issue":"8","key":"10.1002\/14651858.CD000208.pub2-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1176\/ajp.130.8.922","article-title":"Methylphenidate in tardive dyskinesia","volume":"130","author":"Fann","year":"1973","journal-title":"American Journal of Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD000208.pub2-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/BF01000185","article-title":"The effects of electromyographic feedback training on suppression of the oral-lingual movements associated with tardive dyskinesia","volume":"16","author":"Fudge","year":"1991","journal-title":"Biofeedback and Self-Regulation"},{"issue":"2","key":"10.1002\/14651858.CD000208.pub2-BIB0064|cit64","first-page":"18","article-title":"Pilot study of cyproheptadine (Periactin) in tardive dyskinesia","volume":"14","author":"Gardos","year":"1978","journal-title":"Psychopharmacolgy Bulletin"},{"issue":"2","key":"10.1002\/14651858.CD000208.pub2-BIB0065|cit65","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1055\/s-0028-1094443","article-title":"Effect of lithium on neuroleptic-induced tardive dyskinesia compared with placebo in a double-blind cross-over trial","volume":"8","author":"Gerlach","year":"1975","journal-title":"Pharmakopsychiatrie, Neuro-Psychopharmakologie"},{"issue":"7","key":"10.1002\/14651858.CD000208.pub2-BIB0066|cit66","first-page":"Supplement P04.","article-title":"No PD dyskinesia scale protects against placebo responses: A comparison of multiple scales","volume":"80","author":"Goetz","year":"2013","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD000208.pub2-BIB0067|cit67","first-page":"S115","article-title":"No PD dyskinesia scale protects against placebo responses: A comparison of seven scales","volume":"28","author":"Goetz","year":"2013","journal-title":"Movement disorders"},{"key":"10.1002\/14651858.CD000208.pub2-BIB0068|cit68","first-page":"41","article-title":"Evaluation of reserpine and alpha-methyldopa in the treatment of tardive dyskinesia","volume":"16","author":"Huang","year":"1980","journal-title":"Psychopharmacology Bulletin"},{"key":"10.1002\/14651858.CD000208.pub2-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/BF00426466","article-title":"Reserpine and alpha-methyldopa in the treatment of tardive dyskinesia","volume":"73","author":"Huang","year":"1981","journal-title":"Psychopharmacology"},{"issue":"2","key":"10.1002\/14651858.CD000208.pub2-BIB0070|cit70","first-page":"138","article-title":"Studies on the action of certain pharmacological agents on tardive dykinesia and on the rabbit syndrome","volume":"9","author":"Jus","year":"1974","journal-title":"International Journal of Clinical Pharmacology"},{"key":"10.1002\/14651858.CD000208.pub2-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1159\/000117629","article-title":"Deanol, lithium and placebo in the treatment of tardive dyskinesia: A double-blind crossover study","volume":"4","author":"Jus","year":"1978","journal-title":"Neuropsychobiology"},{"key":"10.1002\/14651858.CD000208.pub2-BIB0072|cit72","unstructured":"Kabes J Sikora J Pisvejc J Skoudia V Piracetam action in neuroleptic induced extrapyramidal side-effects Proceedings of the 12th CINP congress; Supplement to Progress in Neuropsychopharmacology Pergamon Press 1980"},{"issue":"3","key":"10.1002\/14651858.CD000208.pub2-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1159\/000468574","article-title":"Effect of piracetam on extrapyramidal side effects induced by neuroleptic drugs","volume":"17","author":"Kabes","year":"1982","journal-title":"International Pharmacopsychiatry"},{"key":"10.1002\/14651858.CD000208.pub2-BIB0074|cit74","unstructured":"Kabes J Sikora J Pisvejc J Skoudia V Piracetam action in neuroleptic induced extrapyramidal side-effects Proceedings of the 12th Collegium Internationale Neuro-Psychopharmacologicum Congress; 1980 Jun 22-26; Goteborg, Sweden. 1980"},{"issue":"5","key":"10.1002\/14651858.CD000208.pub2-BIB0075|cit75","first-page":"339","article-title":"Piracetam effectivity in tardive dyskinesia. A double-blind placebo-controlled cross-over trial","volume":"79","author":"Kabes","year":"1983","journal-title":"Ceskoslovenska Psychiatrie"},{"issue":"2","key":"10.1002\/14651858.CD000208.pub2-BIB0076|cit76","first-page":"137","article-title":"Management of neuroleptic side-effects with piracetam","volume":"77","author":"Sikora","year":"1981","journal-title":"Ceskoslovenska Psychiatrie"},{"issue":"1","key":"10.1002\/14651858.CD000208.pub2-BIB0077|cit77","first-page":"64","article-title":"Dose-dependent effect of piracetam in tardive-dyskinesia - double-blind placebo controlled trial","volume":"27","author":"Kabes","year":"1985","journal-title":"Activitas Nervosa Superior"},{"issue":"5","key":"10.1002\/14651858.CD000208.pub2-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1212\/WNL.32.5.547","article-title":"Estrogen treatment of dyskinetic disorders","volume":"32","author":"Koller","year":"1982","journal-title":"Neurology"},{"issue":"4","key":"10.1002\/14651858.CD000208.pub2-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/BF00432752","article-title":"Vasopressin in anergic schizophrenia: a cross-over study with lysine-8-vasopressin and placebo","volume":"74","author":"Korsgaard","year":"1981","journal-title":"Psychopharmacology"},{"key":"10.1002\/14651858.CD000208.pub2-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1001\/archpsyc.1987.01800190013002","article-title":"Prediction of relapse in schizophrenia","volume":"44","author":"Lieberman","year":"1987","journal-title":"Archives of General Psychiatry"},{"key":"10.1002\/14651858.CD000208.pub2-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/npp.1994.40","article-title":"Methylphenidate response, psychopathology and tardive dyskinesia as predictors of relapse in schizophrenia","volume":"11","author":"Lieberman","year":"1994","journal-title":"Neuropyschopharmacology"},{"issue":"1","key":"10.1002\/14651858.CD000208.pub2-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/0165-1781(88)90083-2","article-title":"High-dose naloxone in tardive dyskinesia","volume":"26","author":"Lindenmayer","year":"1988","journal-title":"Psychiatry Research"},{"issue":"10","key":"10.1002\/14651858.CD000208.pub2-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1176\/ajp.137.10.1202","article-title":"Identification of a subgroup of tardive dyskinesia patients by pharmacologic probes","volume":"137","author":"Moore","year":"1980","journal-title":"American Journal of Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD000208.pub2-BIB0084|cit84","first-page":"56","article-title":"Pharmacologic probes of neurotransmitter systems in tardive dyskinesia: implications for clinical management","volume":"47","author":"Nasrallah","year":"1986","journal-title":"Journal of Clinical Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD000208.pub2-BIB0085|cit85","first-page":"277","article-title":"GM1 ganglioside as a potential treatment in tardive dyskinesia","volume":"25","author":"Peselow","year":"1989","journal-title":"Psychopharmacology Bulletin"},{"key":"10.1002\/14651858.CD000208.pub2-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1177\/089198879400700408","article-title":"Changes in tardive dyskinesia symptoms in elderly patients treated with ganglioside GM1 or placebo","volume":"7","author":"Sommer","year":"1994","journal-title":"Journal of Geriatric Psychiatry and Neurology"},{"key":"10.1002\/14651858.CD000208.pub2-BIB0087|cit87","first-page":"36","article-title":"Preliminary experience with tryptophan and lithium in the treatment of tardive dyskinesia","volume":"9","author":"Prange","year":"1973","journal-title":"Psychopharmacology Bulletin"},{"key":"10.1002\/14651858.CD000208.pub2-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1176\/ajp.132.5.560","article-title":"Lithium carbonate in the treatment of tardive dyskinesia","volume":"132","author":"Reda","year":"1975","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD000208.pub2-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1056\/NEJM197410172911617","article-title":"Treatment of tardive dyskinesia with lithium carbonate","volume":"291","author":"Reda","year":"1974","journal-title":"New England Journal of Medicine"},{"issue":"3","key":"10.1002\/14651858.CD000208.pub2-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/0165-1781(82)90068-3","article-title":"Naloxone, tardive dyskinesia, and endogenous beta-endorphin","volume":"7","author":"Reker","year":"1982","journal-title":"Psychiatry Research"},{"key":"10.1002\/14651858.CD000208.pub2-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/j.1749-6632.1982.tb39480.x","article-title":"Naloxone and naltrexone in mental illness and tardive dyskinesia","volume":"398","author":"Volavka","year":"1982","journal-title":"Annals of New York Academy of Sciences"},{"key":"10.1002\/14651858.CD000208.pub2-BIB0092|cit92","unstructured":"Shah BB Connolly B Mestre TA Prashanth LK Miyasaki JM Steeves T Famotidine for the treatment of levodopa-induced dyskinesia: An ongoing \"N-of-1'' Study 26th Annual Symposium on Etiology, Pathogenesis and Treatment of Movement Disorders 2012"},{"issue":"2","key":"10.1002\/14651858.CD000208.pub2-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1055\/s-0028-1094481","article-title":"Lithium in tardive dyskinesia","volume":"9","author":"Simpson","year":"1976","journal-title":"Pharmakopsychiatrie neuro-psychopharmakologie"},{"issue":"1","key":"10.1002\/14651858.CD000208.pub2-BIB0094|cit94","first-page":"87","article-title":"An early clinical and toxicity trial of EX 11-582A in chronic schizophrenia","volume":"19","author":"Simpson","year":"1976","journal-title":"Current Therapeutic Research"},{"issue":"6","key":"10.1002\/14651858.CD000208.pub2-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"302","DOI":"10.3928\/0048-5713-19890601-08","article-title":"Gamma-aminobutyric-acid (GABA) pathways in tardive dyskinesia","volume":"19","author":"Nguyen","year":"1989","journal-title":"Psychiatric Annals"},{"key":"10.1002\/14651858.CD000208.pub2-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S0140-6736(83)90075-2","article-title":"GABA agonist treatment improves tardive dyskinesia","volume":"2","author":"Tamminga","year":"1983","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD000208.pub2-BIB0097|cit97","article-title":"Tardive dyskinesia: GABA agonist treatment","volume-title":"Catecholamines: Neuropharmacology and Central Nervous System - Therapeutic Aspects","author":"Tamminga","year":"1994"},{"issue":"3","key":"10.1002\/14651858.CD000208.pub2-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/0165-1781(89)90146-7","article-title":"A double blind trial of essential fatty acid supplementation in patients with tardive dyskinesia","volume":"27","author":"Vaddadi","year":"1989","journal-title":"Psychiatry Research"},{"key":"10.1002\/14651858.CD000208.pub2-BIB0099|cit99","first-page":"333","article-title":"Essential fatty acids, tardive dyskinesia, and schizophrenia","volume-title":"Pathophysiology and Roles in Clinical Medicine","author":"Vaddadi","year":"1990"},{"issue":"1","key":"10.1002\/14651858.CD000208.pub2-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/00001756-200201210-00011","article-title":"A randomised, placebo-controlled, double blind study of treatment of Huntington's disease with unsaturated fatty acids","volume":"13","author":"Vaddadi","year":"2002","journal-title":"Neuroreport"},{"key":"10.1002\/14651858.CD000208.pub2-BIB0101|cit101","doi-asserted-by":"crossref","unstructured":"Villeneuve A B\u00f6sz\u00f6rm\u00e9nyi Z Treatment of drug-induced dyskinesias Lancet 1970","DOI":"10.1016\/S0140-6736(70)90724-5"},{"issue":"3","key":"10.1002\/14651858.CD000208.pub2-BIB0102|cit102","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1159\/000117746","article-title":"Estrogens in tardive dyskinesia in male psychiatric patients","volume":"6","author":"Villeneuve","year":"1980","journal-title":"Neuropsychobiology"},{"issue":"2","key":"10.1002\/14651858.CD000208.pub2-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/0165-1781(86)90002-8","article-title":"Lithium and lecithin in tardive dyskinesia: an update","volume":"19","author":"Volavka","year":"1986","journal-title":"Psychiatry Research"},{"issue":"4","key":"10.1002\/14651858.CD000208.pub2-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1097\/01.jcp.0000132440.27854.44","article-title":"Naltrexone treatment of tardive dyskinesia in patients with schizophrenia","volume":"24","author":"Wonodi","year":"2004","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD000208.pub2-BIB0105|cit105","unstructured":"EUCTR-003135-19-PL A randomized, double-blind, placebo-controlled, fixed-dose study of sd-809 (deutetrabenazine) for the treatment of moderate to severe tardive dyskinesia - addressing involuntary movements in tardive dyskinesia (aim-td) study http:\/\/apps.who.int\/trialsearch\/Trial2.aspx?TrialID=EUCTR2014-003135-19-PL 2014"},{"key":"10.1002\/14651858.CD000208.pub2-BIB0106|cit106","first-page":"S294","article-title":"A randomized, double-blind, placebo-controlled trial of deutetrabenazine for the treatment of tardive dyskinesia (ARM-TD)","volume":"31","author":"Fernandez","year":"2016","journal-title":"Movement Disorders"},{"key":"10.1002\/14651858.CD000208.pub2-BIB0107|cit107","unstructured":"NCT02195700 A randomized, double-blind, placebo-controlled study of SD-809 (Deutetrabenazine) for the treatment of moderate to severe tardive dyskinesia www.Clinicaltrials.gov 2014"},{"key":"10.1002\/14651858.CD000208.pub2-BIB0108|cit108","first-page":"S692","article-title":"KINECT 3: A randomized, double-blind, placebo-controlled phase 3 trial of valbenazine (NBI-98854) for tardive dyskinesia","volume":"31","author":"Factor","year":"2016","journal-title":"Movement Disorders"},{"key":"10.1002\/14651858.CD000208.pub2-BIB0109|cit109","first-page":"S213","article-title":"Efficacy of Valbenazine (NBI-98854) in in subjects with tardive dyskinesia: results of a long-term extension study (KINECT 3 Extension)","volume":"41","author":"Grigoriadis","year":"2016","journal-title":"Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD000208.pub2-BIB0110|cit110","doi-asserted-by":"crossref","unstructured":"Hauser R Factor S Marder S Knesevich MA Ramirez PM Jimenez R KINECT 3: A randomized, double-blind, placebo-controlled phase 3 trial of valbenazine (NBI-98854) for tardivedyskinesia Neurology 68th American Academy of Neurology Annual Meeting 2016","DOI":"10.1176\/appi.ajp.2017.16091037"},{"key":"10.1002\/14651858.CD000208.pub2-BIB0111|cit111","unstructured":"NCT02274558 A phase 3 study of NBI-98854 for the treatment of tardive dyskinesia https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02274558 (accessed on 6 October 2017) 2014"},{"key":"10.1002\/14651858.CD000208.pub2-BIB0112|cit112","unstructured":"NCT01393600 Nbi-98854 for the treatment of tardive dyskinesia in subjects with schizophrenia or schizoaffective disorder www.Clinicaltrials.gov 2011"},{"key":"10.1002\/14651858.CD000208.pub2-BIB0113|cit113","first-page":"S691","article-title":"Effect of right DLPFC-repetitive transcranial magnetic stimulation (rTMS) on tardive dyskinesia in patients with psychosis","volume":"31","author":"Pattojoshi","year":"2016","journal-title":"Movement Disorders"},{"issue":"6","key":"10.1002\/14651858.CD000208.pub2-BIB0114|cit114","first-page":"843","article-title":"A randomized controlled study of Ginkgo biloba extract on tardive dyskinesia","volume":"14","author":"Xu","year":"2012","journal-title":"Journal of Chinese Physician"},{"key":"10.1002\/14651858.CD000208.pub2-BIB0115|cit115","first-page":"P","article-title":"Double-blind placebo controlled study using buspirone in the treatment of tardive dyskinesia","volume":"27","author":"Garcia","year":"1992","journal-title":"ASHP Midyear Clinical Meeting"},{"key":"10.1002\/14651858.CD000208.pub2-BIB0116|cit116","unstructured":"ISRCTN14688109 Investigation of the potential beneficial effects of cannabidiol in the treatment of tardive dyskinesia http:\/\/www.isrctn.com 2015"},{"key":"10.1002\/14651858.CD000208.pub2-BIB0117|cit117","unstructured":"NCT00621634 Efficacy of docosahexaenoic acid on tardive dyskinesia www.Clinicaltrials.gov 2008"},{"key":"10.1002\/14651858.CD000208.pub2-BIB0118|cit118","unstructured":"NCT01391390 Melatonin treatment for tardive dyskinesia in schizophrenia www.Clinicaltrials.gov 2011"},{"key":"10.1002\/14651858.CD000208.pub2-BIB0119|cit119","unstructured":"NCT01688037 NBI-98854 for the treatment of tardive dyskinesia in subjects with schizophrenia or schizoaffective disorder (KINECT study) www.Clinicaltrials.gov 2012"},{"key":"10.1002\/14651858.CD000208.pub2-BIB0120|cit120","unstructured":"NCT01804920 D-Serine treatment for tardive dyskinesia www.Clinicaltrials.gov 2013"},{"key":"10.1002\/14651858.CD000208.pub2-BIB0121|cit121","unstructured":"NCT02291861 Addressing involuntary movements in tardive dyskinesia www.ClinicalTrials.gov 2014"},{"issue":"4","key":"10.1002\/14651858.CD000208.pub2-BIB0122|cit122","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000203.pub3","article-title":"Gamma-aminobutyric acid agonists for neuroleptic-induced tardive dyskinesia","author":"Alabed","year":"2011","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD000208.pub2-BIB0123|cit123","doi-asserted-by":"crossref","first-page":"160","DOI":"10.4321\/S0213-61632013000300002","article-title":"Treatment of tardive dyskinesia: A systematic review (1997-2011)","volume":"27","author":"Alimi","year":"2013","journal-title":"European Journal of Psychiatry"},{"issue":"7066","key":"10.1002\/14651858.CD000208.pub2-BIB0124|cit124","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1136\/bmj.313.7066.1200","article-title":"Detecting skewness from summary information","volume":"313","author":"Altman","year":"1996","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD000208.pub2-BIB0125|cit125","article-title":"Tardive dyskinesia: a task force report of the American Psychiatric Association","volume-title":"American Psychiatric Association","author":"American Psychiatric Association","year":"1992"},{"key":"10.1002\/14651858.CD000208.pub2-BIB0126|cit126","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2125.1991.tb05604.x","article-title":"Should we cross off the crossover?","volume":"32","author":"Armitage","year":"1991","journal-title":"Journal of Clinical Pharmacology"},{"key":"10.1002\/14651858.CD000208.pub2-BIB0127|cit127","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.4088\/JCP.v69n1008","article-title":"Tardive dyskinesia and the 3-year course of schizophrenia: results from a large, prospective, naturalistic study","volume":"69","author":"Ascher-Svanum","year":"2008","journal-title":"Journal of Clinical Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD000208.pub2-BIB0128|cit128","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1097\/00004714-200004000-00011","article-title":"Tardive dyskinesia associated with higher mortality in psychiatric patients: results of a meta-analysis of seven independent studies","volume":"20","author":"Ballesteros","year":"2000","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD000208.pub2-BIB0129|cit129","doi-asserted-by":"crossref","DOI":"10.1016\/B978-0-12-079035-7.50021-X","article-title":"The side-effects of antipsychotic drugs. I. CNS and neuromuscular effects","volume-title":"Antipsychotic Drugs and their Side-effects","author":"Barnes","year":"1993"},{"key":"10.1002\/14651858.CD000208.pub2-BIB0130|cit130","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1192\/bjp.144.5.498","article-title":"Tardive dyskinesia: fluctuating patient or fluctuating rater","volume":"144","author":"Bergen","year":"1984","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD000208.pub2-BIB0131|cit131","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1192\/bjp.154.4.523","article-title":"The course of tardive dyskinesia in patients on long-term neuroleptics","volume":"154","author":"Bergen","year":"1989","journal-title":"British Journal of Psychiatry"},{"issue":"43","key":"10.1002\/14651858.CD000208.pub2-BIB0132|cit132","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta21430","article-title":"Systematic review of interventions for treating or preventing antipsychotic-induced tardive dyskinesia","volume":"21","author":"Bergman","year":"2017 Aug","journal-title":"Health Technology Assessment"},{"issue":"1","key":"10.1002\/14651858.CD000208.pub2-BIB0133|cit133","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000205.pub3","article-title":"Benzodiazepines for antipsychotic-induced tardive dyskinesia","author":"Bergman","year":"2018","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD000208.pub2-BIB0134|cit134","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000204.pub2","article-title":"Anticholinergic medication for antipsychotic-induced tardive dyskinesia","author":"Bergman","year":"2018","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD000208.pub2-BIB0135|cit135","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1136\/bmj.315.7108.600","article-title":"Statistics notes. Trials randomised in clusters","volume":"315","author":"Bland","year":"1997","journal-title":"BMJ"},{"issue":"4","key":"10.1002\/14651858.CD000208.pub2-BIB0136|cit136","first-page":"405","article-title":"The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use","volume":"54","author":"Boissel","year":"1999","journal-title":"Therapie"},{"key":"10.1002\/14651858.CD000208.pub2-BIB0137|cit137","unstructured":"Brooks M FDA OKs Deutetrabenazine (Austedo) for Tardive Dyskinesia www.Medscape.com, available from: https:\/\/www.medscape.com\/viewarticle\/885051 (accessed on 13 Oct 2017) 2017"},{"key":"10.1002\/14651858.CD000208.pub2-BIB0138|cit138","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/j.1749-6632.1989.tb14918.x","article-title":"Possible involvement of free radical in neuroleptic-induced movement disorders","volume":"570","author":"Cadet","year":"1989","journal-title":"Annals of the New York Academy of Sciences"},{"key":"10.1002\/14651858.CD000208.pub2-BIB0139|cit139","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1056\/NEJM199403103301006","article-title":"Schizophrenia","volume":"330","author":"Carpenter","year":"1994","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD000208.pub2-BIB0140|cit140","article-title":"Tardive dyskinesia: pathophysiology","volume-title":"Psychopharmacology. The Fourth Generation of Progress","author":"Casey","year":"1994"},{"issue":"3","key":"10.1002\/14651858.CD000208.pub2-BIB0141|cit141","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/npp.1993.26","article-title":"Tardive dyskinesia outcomes: clinical and pharmacologic correlates of remission and persistence","volume":"8","author":"Cavallaro","year":"1993","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"10.1002\/14651858.CD000208.pub2-BIB0142|cit142","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1097\/JCP.0b013e3181929f94","article-title":"Mortality rates among patients with schizophrenia and tardive dyskinesia","volume":"29","author":"Chong","year":"2009","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD000208.pub2-BIB0143|cit143","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.schres.2005.02.013","article-title":"Manual for the Extrapyramidal Symptom Rating Scale (ESRS)","volume":"76","author":"Chouinard","year":"2005","journal-title":"Schizophrenia Research"},{"issue":"2","key":"10.1002\/14651858.CD000208.pub2-BIB0144|cit144","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1159\/000112883","article-title":"Atypical antipsychotics: CATIE study, drug-induced movement disorder and resulting iatrogenic psychiatric-like symptoms, supersensitivity rebound psychosis and withdrawal discontinuation syndromes","volume":"77","author":"Chouinard","year":"2008","journal-title":"Psychotherapy and Psychosomatics"},{"key":"10.1002\/14651858.CD000208.pub2-BIB0145|cit145","unstructured":"Clarke M Oxman AD Cochrane Collaboration Handbook The Cochrane Library [database on disk and CDROM]. The Cochrane Collaboration 2000"},{"issue":"1","key":"10.1002\/14651858.CD000208.pub2-BIB0146|cit146","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1007\/s13311-013-0222-5","article-title":"Tardive dyskinesia: therapeutic options for an increasingly common disorde","volume":"11","author":"Cloud","year":"2014","journal-title":"Neurotherapeutics"},{"issue":"3","key":"10.1002\/14651858.CD000208.pub2-BIB0147|cit147","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1176\/appi.ajp.161.3.414","article-title":"Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies","volume":"161","author":"Correll","year":"2004","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD000208.pub2-BIB0148|cit148","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1097\/YCO.0b013e3282f53132","article-title":"Tardive dyskinesia and new antipsychotics","volume":"21","author":"Correll","year":"2008","journal-title":"Current Opinion in Psychiatry"},{"key":"10.1002\/14651858.CD000208.pub2-BIB0149|cit149","unstructured":"Deeks J Issues in the selection for meta-analyses of binary data Proceedings of the 8th International Cochrane Colloquium; 2000 Oct 25-28; Cape Town Cape Town The Cochrane Collaboration 2000"},{"key":"10.1002\/14651858.CD000208.pub2-BIB0150|cit150","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/BF02599201","article-title":"The unit of analysis error in studies about physicians' patient care behavior","volume":"7","author":"Divine","year":"1992","journal-title":"Journal of General Internal Medicine"},{"key":"10.1002\/14651858.CD000208.pub2-BIB0151|cit151","doi-asserted-by":"crossref","first-page":"2971","DOI":"10.1002\/sim.1301","article-title":"Issues in the meta-analysis of cluster randomized trials","volume":"21","author":"Donner","year":"2002","journal-title":"Statistics in Medicine"},{"key":"10.1002\/14651858.CD000208.pub2-BIB0152|cit152","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"issue":"1","key":"10.1002\/14651858.CD000208.pub2-BIB0153|cit153","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000458.pub2","article-title":"Non-neuroleptic catecholaminergic drugs for neuroleptic-induced tardive dyskinesia","author":"El-Sayeh","year":"2006","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD000208.pub2-BIB0154|cit154","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/ije\/31.1.140","article-title":"Meta-analyses involving cross-over trials: methodological issues","volume":"31","author":"Elbourne","year":"2002","journal-title":"International Journal of Epidemiology"},{"issue":"11","key":"10.1002\/14651858.CD000208.pub2-BIB0155|cit155","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000206.pub3","article-title":"Calcium channel blockers for neuroleptic-induced tardive dyskinesia","author":"Essali","year":"2011","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD000208.pub2-BIB0156|cit156","unstructured":"US Food Drug Administration FDA approves first drug to treat tardive dyskinesia www.fda.gov, available from: https:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm552418.htm (accessed on 13 Oct 2017) 2017"},{"key":"10.1002\/14651858.CD000208.pub2-BIB0157|cit157","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1212\/WNL.56.6.805","article-title":"The course of tardive dyskinesia and parkinsonism in psychiatric inpatients: 14-year follow-up","volume":"56","author":"Fernandez","year":"2001","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD000208.pub2-BIB0158|cit158","article-title":"The crossover study","volume-title":"The Design and Analysis of Clinical Experiments","author":"Fleiss","year":"1984"},{"issue":"7","key":"10.1002\/14651858.CD000208.pub2-BIB0159|cit159","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jclinepi.2005.06.006","article-title":"Imputing missing standard deviations in meta-analyses can provide accurate results","volume":"59","author":"Furukawa","year":"2006","journal-title":"Journal of Clinical Epidemiology"},{"issue":"4","key":"10.1002\/14651858.CD000208.pub2-BIB0160|cit160","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/j.1600-0447.1993.tb03366.x","article-title":"The St. Hans Rating Scale for extrapyramidal syndromes: reliability and validity","volume":"87","author":"Gerlach","year":"1993","journal-title":"Acta Psychiatrica Scandinavica"},{"key":"10.1002\/14651858.CD000208.pub2-BIB0161|cit161","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1192\/bjp.157.4.585","article-title":"Predictors of improvement in tardive dyskinesia following discontinuation of neuroleptic medication","volume":"157","author":"Glazer","year":"1990","journal-title":"British Journal of Psychiatry"},{"issue":"suppl 4","key":"10.1002\/14651858.CD000208.pub2-BIB0162|cit162","first-page":"15","article-title":"Review of incidence studies of tardive dyskinesia associated with typical antipsychotics","volume":"61","author":"Glazer","year":"2000","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD000208.pub2-BIB0163|cit163","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1093\/oxfordjournals.aje.a009904","article-title":"Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994","volume":"149","author":"Gulliford","year":"1999","journal-title":"American Journal of Epidemiology"},{"key":"10.1002\/14651858.CD000208.pub2-BIB0164|cit164","article-title":"ECDEU","volume-title":"Assessment Manual for Psychopharmacology, Revised","author":"Guy","year":"1976"},{"key":"10.1002\/14651858.CD000208.pub2-BIB0165|cit165","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD000208.pub2-BIB0166|cit166","doi-asserted-by":"crossref","unstructured":"Higgins JPT Green S (editors) Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2009] The Cochrane Collaboration, 2009 www.cochrane-handbook.org 2009","DOI":"10.1002\/9780470712184"},{"key":"10.1002\/14651858.CD000208.pub2-BIB0167|cit167","unstructured":"Higgins JPT Green S (editors) Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org."},{"issue":"suppl 4","key":"10.1002\/14651858.CD000208.pub2-BIB0168|cit168","first-page":"27","article-title":"Tardive dyskinesia in older patients","volume":"61","author":"Jeste","year":"2000","journal-title":"Journal of Clinical Psychiatry"},{"issue":"7303","key":"10.1002\/14651858.CD000208.pub2-BIB0169|cit169","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1136\/bmj.323.7303.42","article-title":"Systematic reviews in health care: assessing the quality of controlled clinical trials","volume":"323","author":"J\u0171ni","year":"2001","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD000208.pub2-BIB0170|cit170","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1001\/archpsyc.1982.04290040069010","article-title":"Tardive dyskinesia: prevalence and risk factors, 1959 to 1979","volume":"39","author":"Kane","year":"1982","journal-title":"Archives of General Psychiatry"},{"key":"10.1002\/14651858.CD000208.pub2-BIB0171|cit171","volume-title":"Positive and Negative Syndrome Scale (PANSS) manual","author":"Kay","year":"1986"},{"issue":"2","key":"10.1002\/14651858.CD000208.pub2-BIB0172|cit172","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The Positive and Negative Syndrome Scale (PANSS) for Schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophrenia Bulletin"},{"issue":"11","key":"10.1002\/14651858.CD000208.pub2-BIB0173|cit173","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/j.biopsych.2005.10.020","article-title":"Attrition in randomized controlled clinical trials: methodological issues in psychopharmacology","volume":"59","author":"Leon","year":"2006","journal-title":"Biological Psychiatry"},{"key":"10.1002\/14651858.CD000208.pub2-BIB0174|cit174","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1192\/bjp.187.4.366","article-title":"Clinical implications of Brief Psychiatric Rating Scale Scores","volume":"187","author":"Leucht","year":"2005","journal-title":"British Journal of Psychiatry"},{"issue":"2-3","key":"10.1002\/14651858.CD000208.pub2-BIB0175|cit175","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.schres.2005.04.008","article-title":"What does the PANSS mean?","volume":"79","author":"Leucht","year":"2005","journal-title":"Schizophrenia Research"},{"issue":"Supplement 29","key":"10.1002\/14651858.CD000208.pub2-BIB0176|cit176","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1192\/S0007125000298255","article-title":"Introduction","volume":"168","author":"Lieberman","year":"1996","journal-title":"British Journal of Psychiatry"},{"issue":"5 Suppl B","key":"10.1002\/14651858.CD000208.pub2-BIB0177|cit177","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.18553\/jmcp.2012.18.S5-B.1","article-title":"Summary of the comparative effectiveness review on off-label use of atypical antipsychotics","volume":"18","author":"Maher","year":"2012","journal-title":"Journal of Managed Care Pharmacy"},{"key":"10.1002\/14651858.CD000208.pub2-BIB0178|cit178","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1192\/bjp.176.3.249","article-title":"Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia","volume":"176","author":"Marshall","year":"2000","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD000208.pub2-BIB0179|cit179","first-page":"44","article-title":"Prevalence of tardive dyskinesia and all-cause mortality amongst patients in a large psychiatric institute in Rio de Janeiro","volume":"38","author":"Martins","year":"2011","journal-title":"Revista de Psiquiatria Cl\u00ednica"},{"issue":"9263","key":"10.1002\/14651858.CD000208.pub2-BIB0180|cit180","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1016\/S0140-6736(00)04337-3","article-title":"The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials","volume":"357","author":"Moher","year":"2001","journal-title":"Lancet"},{"issue":"7","key":"10.1002\/14651858.CD000208.pub2-BIB0181|cit181","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1345\/aph.1C460","article-title":"Melatonin for the treatment of tardive dyskinesia","volume":"37","author":"Nelson","year":"2003","journal-title":"Annals of Pharmacotherapy"},{"key":"10.1002\/14651858.CD000208.pub2-BIB0182|cit182","unstructured":"NICE Psychosis and schizophrenia in adults: treatment and management NICE clinical guideline 178 (guidance.nice.org.uk\/cg178) 2014"},{"key":"10.1002\/14651858.CD000208.pub2-BIB0183|cit183","doi-asserted-by":"crossref","first-page":"799","DOI":"10.2466\/pr0.1962.10.3.799","article-title":"The Brief Psychiatric Rating Scale","volume":"10","author":"Overall","year":"1962","journal-title":"Psychological Reports"},{"key":"10.1002\/14651858.CD000208.pub2-BIB0184|cit184","article-title":"Crossover trials","volume-title":"Clinical trials. A Practical Approach","author":"Pocock","year":"1983"},{"issue":"5","key":"10.1002\/14651858.CD000208.pub2-BIB0185|cit185","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1037\/h0043220","article-title":"A continuous performance test of brain damage","volume":"20","author":"Rosvold","year":"1956","journal-title":"Journal of Consulting Psychology"},{"key":"10.1002\/14651858.CD000208.pub2-BIB0186|cit186","volume-title":"Modern Psychometrics","author":"Rust","year":"1989"},{"issue":"3","key":"10.1002\/14651858.CD000208.pub2-BIB0187|cit187","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1080\/j.1440-1614.2000.00737.x","article-title":"The current status of tardive dyskinesia","volume":"34","author":"Sachdev","year":"2000","journal-title":"Australian and New Zealand Journal of Psychiatry"},{"key":"10.1002\/14651858.CD000208.pub2-BIB0188|cit188","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1017\/S0924933800002625","article-title":"Treatment of tardive dyskinesias with vitamin E","volume":"6","author":"Schmidt","year":"1991","journal-title":"European Psychiatry"},{"key":"10.1002\/14651858.CD000208.pub2-BIB0189|cit189","first-page":"431","article-title":"Clinical research for the treatment of schizophrenia","volume":"29","author":"Schooler","year":"1993","journal-title":"Psychopharmacology Bulletin"},{"key":"10.1002\/14651858.CD000208.pub2-BIB0190|cit190","unstructured":"Sch\u00fcnemann HJ Oxman AD Vist GE Higgins JPT Deeks JJ Glasziou P Chapter 12: Interpreting results and drawing conclusions. In Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"issue":"4","key":"10.1002\/14651858.CD000208.pub2-BIB0191|cit191","doi-asserted-by":"crossref","first-page":"209","DOI":"10.15171\/bi.2017.25","article-title":"Study-based registers of randomized controlled trials: Starting a systematic review with data extraction or meta-analysis","volume":"7","author":"Shokraneh","year":"2017","journal-title":"BioImpacts"},{"key":"10.1002\/14651858.CD000208.pub2-BIB0192|cit192","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/BF00496058","article-title":"A rating scale for tardive dyskinesia","volume":"64","author":"Simpson","year":"1979","journal-title":"Psychopharmacology"},{"key":"10.1002\/14651858.CD000208.pub2-BIB0193|cit193","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1001\/archpsyc.1980.01780250054006","article-title":"Changes in prevalence, severity and recovery in tardive dyskinesia with age","volume":"37","author":"Smith","year":"1980","journal-title":"Archives of General Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD000208.pub2-BIB0194|cit194","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000459.pub2","article-title":"Neuroleptic reduction and\/or cessation and neuroleptics as specific treatments for tardive dyskinesia","author":"Soares-Weiser","year":"2006","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD000208.pub2-BIB0195|cit195","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000209.pub2","article-title":"Vitamin E for neuroleptic-induced tardive dyskinesia","author":"Soares-Weiser","year":"2011","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD000208.pub2-BIB0196|cit196","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000207","article-title":"Cholinergic medication for neuroleptic induced-tardive dyskinesia","author":"Tammenmaa","year":"2002","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD000208.pub2-BIB0197|cit197","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/B978-0-444-52014-2.00043-4","article-title":"Epidemiology of tardive dyskinesia before and during the era of modern antipsychotic drugs","volume":"100","author":"Tarsy","year":"2011","journal-title":"Handbook of Clinical Neurology"},{"key":"10.1002\/14651858.CD000208.pub2-BIB0198|cit198","doi-asserted-by":"crossref","DOI":"10.3109\/9780203092835","volume-title":"The Maudsley Prescribing Guidelines (10th Edition)","author":"Taylor","year":"2009"},{"issue":"5","key":"10.1002\/14651858.CD000208.pub2-BIB0199|cit199","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta3050","article-title":"Methods for evaluating area-wide and organistation-based intervention in health and health care: a systematic review","volume":"3","author":"Ukoumunne","year":"1999","journal-title":"Health Technology Assessment"},{"key":"10.1002\/14651858.CD000208.pub2-BIB0200|cit200","volume-title":"Wechsler Memory Scale","author":"Wechsler","year":"1945"},{"key":"10.1002\/14651858.CD000208.pub2-BIB0201|cit201","doi-asserted-by":"crossref","DOI":"10.1037\/11167-000","article-title":"The Measurement and Appraisal of Adult Intelligence (4th ed.)","volume-title":"The Measurement and Appraisal of Adult Intelligence","author":"Wechsler","year":"1958"},{"key":"10.1002\/14651858.CD000208.pub2-BIB0202|cit202","unstructured":"Xia J Adams CE Bhagat N Bhagat V Bhoopathi P El-Sayeh H The Leeds Outcomes Stakeholders Survey (LOSS) Study Proceddings of the15th Cochrane Colloquium; 2007 Oct 23-27; Sao Paulo 2007"},{"issue":"7","key":"10.1002\/14651858.CD000208.pub2-BIB0203|cit203","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1192\/pb.bp.108.021949","article-title":"Loss to outcomes stakeholder survey: the LOSS study","volume":"33","author":"Xia","year":"2009","journal-title":"Psychiatric Bulletin"},{"issue":"3","key":"10.1002\/14651858.CD000208.pub2-BIB0204|cit204","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1055\/s-0042-102884","article-title":"Extract of Ginkgo biloba for tardive dyskinesia: Meta-analysis of randomized controlled trials","volume":"49","author":"Zheng","year":"2016","journal-title":"Pharmacopsychiatry"},{"issue":"2","key":"10.1002\/14651858.CD000208.pub2-BIB0205|cit205","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000208","article-title":"Miscellaneous treatments for tardive dyskinesia","author":"McGrath","year":"2000","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD000208.pub2-BIB0206|cit206","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000208","article-title":"Miscellaneous treatments for neuroleptic-induced tardive dyskinesia","author":"Soares-Weiser","year":"2003","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD000208.pub2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,2]],"date-time":"2024-07-02T03:28:44Z","timestamp":1719890924000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD000208.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Schizophrenia Group","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2018,3,19]]},"references-count":206,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2018,3]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd000208.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,19]]}}}